» Authors » Paul A Carpenter

Paul A Carpenter

Explore the profile of Paul A Carpenter including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 174
Citations 3981
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Wickline M, Carpenter P, Harris J, Iribarren S, Reding K, Pike K, et al.
Transplant Cell Ther . 2024 Sep; 30(12):1221.e1-1221.e13. PMID: 39303986
Comprehensive survivorship care after hematopoietic cell transplantation (HCT) includes revaccination to restore immunity to vaccine-preventable diseases (VPDs). There is complexity to revaccination in this setting, and revaccination rates are sub-optimal....
12.
Bahakel H, Spieker A, Hayek H, Schuster J, Hamdan L, Dulek D, et al.
J Infect Dis . 2024 Sep; 231(1):e123-e131. PMID: 39279435
Background: Pediatric hematopoietic cell transplant (HCT) recipients are at high risk for morbidity from influenza virus infection. We demonstrated in a primary phase 2 randomized controlled trial that 2 post-HCT...
13.
Kongtim P, Vittayawacharin P, Zou J, Srour S, Shaffer B, Shapiro R, et al.
Transplant Cell Ther . 2024 Sep; 30(12):1139-1154. PMID: 39260570
Donor-specific anti-HLA antibodies (DSA) are an important cause of engraftment failure and may negatively impact survival outcomes of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) using an HLA-mismatched allograft....
14.
Carpenter P, Gooley T, Boiko J, Lee C, Burroughs L, Mehta R, et al.
Blood Adv . 2024 Aug; 8(22):5829-5837. PMID: 39167805
Since 2005, there has been a steady decline in chronic graft-versus-host disease (cGVHD) at the Fred Hutchinson Cancer Center. To better understand this phenomenon, we studied the risk of cGVHD...
15.
Shahid Z, Jain T, Dioverti V, Pennisi M, Mikkilineni L, Thiruvengadam S, et al.
Transplant Cell Ther . 2024 Jul; 30(10):955-969. PMID: 39084261
Chimeric antigen receptor (CAR) T-cell therapy is rapidly advancing, offering promising treatments for patients with hematological malignancy. However, associated infectious complications remain a significant concern because of their contribution to...
16.
Hamilton B, Onstad L, Carpenter P, Pidala J, Jurdi N, Farhadfar N, et al.
Contemp Clin Trials . 2024 Jul; 145:107637. PMID: 39038701
Background: Chronic graft-versus-host disease (GVHD) is a leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation. Despite significant progress in chronic GVHD therapies, challenges remain in understanding...
17.
18.
Pidala J, Onstad L, Baumrin E, Carpenter P, Cutler C, Arai S, et al.
Blood Adv . 2024 Jun; 8(17):4651-4657. PMID: 38885484
Cutaneous sclerosis, a highly morbid subtype of chronic graft-versus-host disease (GVHD), demonstrates limited treatment response under current National Institutes of Health (NIH) response measures. We explored novel sclerosis-specific response measures...
19.
Pidala J, Carpenter P, Onstad L, Pavletic S, Hamilton B, Chen G, et al.
PLoS One . 2024 May; 19(5):e0298026. PMID: 38753616
Chronic graft-versus-host disease (GVHD) is an immune-mediated disorder that causes significant late morbidity and mortality following allogeneic hematopoietic cell transplantation. The "Close Assessment and Testing for Chronic GVHD (CATCH)" study...
20.
Meyers G, Bubalo J, Eckstrom E, Winsnes K, Carpenter P, Artz A, et al.
Transplant Cell Ther . 2024 Apr; 30(7):646-662. PMID: 38663768
Acute encephalopathy, manifesting clinically as delirium, is a common but often unrecognized complication of hematopoietic cell transplantation (HCT). Delirium can occur in patients of any age and is observed after...